News for CureVac N.V. (CVAC)

Operator: Greetings. Welcome to CureVac Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode.

CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ETCompany ParticipantsSarah Fakih - Vice President, Corporate...

Discover CureVac BV's Q4 performance with $14.5M revenue, marking a 35.8% Y/Y drop.

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblas

CureVac (CVAC) reports significant revenue boost in 2024, largely driven by a €400 million payment from GSK. The company maintains a strong cash posit

Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancerPr

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my concerns linger over a weak CVAC pipeline.

U.S. stocks were lower, with the Dow Jones index falling around 200 points on Friday. Shares of Argan, Inc. AGX rose sharply during Friday's session following ...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Shares of Portage Biotech Inc. (PRTG) were up over 100% in after-hours trading on Thursday, following promising preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor, given as a single agent or in combination with anti-PD-1 antibody in a murine model of mesothelioma.

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amend

CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual prope

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock.

Vaccine stocks rise in premarket trading amid a jump in number of flu cases

Moderna stock gains on rising flu cases

Vaccine developer stocks rise as flu activity escalates

Stocks Analysis by MarketBeat.com (Ryan Hasson) covering: iShares Russell 2000 ETF, CureVac NV, HeartCore Enterprises Inc. Read MarketBeat.com (Ryan Hasson)'s latest article on Investing.com

Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately.

CureVac N.V. (NASDAQ:CVAC) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ETCompany ParticipantsSarah Fakih - Vice President of Corporate...